CHAMPIONS ONCOLOGY, INC. financials

CSBR CIK 0000771856

Source: EDGAR filings · Built 2026-06-02T02:44:58Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 6.85M -7.12M 1.10M 4.11M -5.14M 650.00K
EBITDA 6.15M -5.46M -3.16M 2.11M 1.29M -1.10M
Working Capital -1.50M -7.90M -2.28M 2.19M 1.43M 1.19M
Net Debt -3.46M 5.18M -1.37M 531.00K 4.91M -4.54M
Gross Margin 50.15% 41.38% 45.18% 51.88% 47.74% 47.08%
Operating Margin 8.00% -14.67% -9.76% 1.24% 0.89% -5.98%
Net Margin 8.26% -14.51% -9.90% 1.12% 0.88% -6.52%
Return on Equity (ROE) 124.63% 382.34% -115.08% 6.02% 4.87% -41.05%
Return on Assets (ROA) 14.53% -27.84% -15.55% 1.55% 1.31% -10.09%
Current Ratio 0.94× 0.63× 0.90× 1.13× 1.13× 1.10×
Debt-to-Equity 1.68× -4.10× 1.89× 1.05× 1.29× 0.74×
Effective Tax Rate -1.62% 0.44% -1.29% 6.00% 17.16% -6.62%
Cash Conversion Ratio 1.57× 0.84× -0.74× 11.86× -4.64× -1.39×
Accruals Ratio -0.08× -0.04× -0.27× -0.17× 0.07× -0.24×
SBC % of Revenue 1.15% 2.23% 1.60% 1.86% 1.46% 1.87%
CapEx Coverage 13.70× -6.25× 1.38× 2.73× -0.49× 1.29×
Free Cash Flow Per Share $0.48 $-0.53 $0.08 $0.29 $-0.35 $0.05

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 21.67× 192.00× 536.50×
P/FCF 14.90× 60.59× 26.44× 140.62×
FCF Yield 6.71% 1.65% 3.78% 0.71%
EV / EBITDA 15.45× 49.54× 115.30×
P/S 1.73× 1.31× 1.24× 2.11× 3.51× 3.06×
P/B 26.12× 14.37× 11.42× 19.38× 19.27×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 56.94M 50.16M 53.87M 49.11M 41.04M 32.12M
Cost of Goods and Services Sold 28.39M 29.40M 29.53M 23.63M 21.45M 17.00M
Research and Development Expense 6.83M 9.54M 11.54M 9.37M 7.20M 5.85M
Operating Expenses 33.93M
Operating Income (Loss) 4.55M -7.36M -5.26M 607.00K 366.00K -1.92M
Income Tax Expense (Benefit) -75.00K -32.00K 68.00K 35.00K 75.00K 130.00K
Net Income (Loss) Attributable to Parent 4.70M -7.28M -5.33M 548.00K 362.00K -2.09M
Earnings Per Share, Basic $0.34 $-0.54 $-0.39 $0.04 $0.03 $-0.18
Weighted Average Number of Shares Outstanding, Basic 13.66M 13.55M 13.54M 13.20M 13.14M 11.84M
Earnings Per Share, Diluted $0.33 $-0.54 $-0.39 $0.04 $0.02 $-0.18
Weighted Average Number of Shares Outstanding, Diluted 14.27M 13.55M 13.54M 14.16M 14.57M 11.84M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 9.79M 2.62M 10.12M 9.01M 4.69M 8.34M
Assets, Current 22.36M 13.64M 19.46M 19.66M 12.63M 13.50M
Assets 32.34M 26.13M 34.31M 35.38M 27.59M 20.75M
Liabilities, Current 23.85M 21.54M 21.73M 17.48M 11.20M 12.30M
Liabilities 28.57M 28.04M 29.68M 26.28M 20.16M 15.65M
Stockholders' Equity Attributable to Parent 3.77M -1.90M 4.64M 9.10M 7.43M 5.10M
Common Stock, Shares, Outstanding 13.78M 13.59M 13.54M 13.52M 13.41M 12.73M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 7.39M -6.14M 3.97M 6.50M -1.68M 2.90M
Payments to Acquire Property, Plant, and Equipment 389.00K 836.00K 2.87M 2.38M 3.28M 2.22M
Net Cash Provided by (Used in) Investing Activities -389.00K -836.00K -2.87M -2.38M -3.17M -2.22M
Payments for Repurchase of Common Stock 0 634.00K 74.00K 0
Net Cash Provided by (Used in) Financing Activities 170.00K -527.00K 11.00K 207.00K 1.20M 4.42M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (CSBR CIK 0000771856), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

ALRS

ALERUS FINANCIAL CORP

GBCI

GLACIER BANCORP, INC.

PLX

PROTALIX BIOTHERAPEUTICS, INC.